Blomia Tropicalis (Blo t 21) IgE Test · Blood

If you live in a warm, humid climate and your nose runs year-round, your chest tightens at night, or your eczema flares without obvious triggers, a tropical dust mite called Blomia tropicalis may be a hidden culprit. This test looks for a specific antibody, Blo t 21 IgE (immunoglobulin E against the Blo t 21 protein), that signals your immune system has decided this mite is an enemy.

Most allergy panels lean heavily on the European dust mites (Dermatophagoides species) and can miss people whose problem is actually Blomia. Knowing whether your immune system reacts to Blo t 21 can sharpen the diagnosis and help target treatment, particularly the choice of allergy shots or sublingual drops.

What This Test Actually Measures

Blo t 21 is one of the major allergens produced by Blomia tropicalis, a mite that thrives in tropical and subtropical homes. It is a small protein found mainly in the mite's gut and droppings, which become airborne in house dust. When you breathe it in repeatedly, some people's immune systems start making IgE antibodies that lock onto Blo t 21 and trigger allergy symptoms on later exposure.

The blood test does not measure damage to your lungs or sinuses. It quantifies how much Blo t 21-specific IgE is circulating in your serum. A positive result means your immune system has already decided to react to this particular protein. The number is a marker of sensitization, not a direct measure of how sick you feel.

Blo t 21 is what allergists call a major allergen. In one Singapore cohort of allergy-clinic patients, a majority had positive IgE to Blo t 21. Among adults with persistent allergic rhinitis in that same study, the great majority reacted to Blo t 21 on blood testing and on skin prick testing. In other words, when Blomia is the driver, Blo t 21 is usually involved.

Why You Should Care: Allergic Rhinitis

Sensitization to Blo t 21 is tightly linked to persistent runny nose, congestion, and sneezing. In the Singapore cohort, the overwhelming majority of adults with persistent rhinitis had Blo t 21 IgE. In a Malaysian study of allergic patients, sensitization to Blo t 21 (along with related Blomia components) was a risk factor for allergic rhinitis.

What this means for you: if standard dust mite testing comes back negative or only weakly positive and you still have year-round nasal symptoms, especially if you live in or recently moved from a tropical or subtropical region, checking Blo t 21 IgE can fill in a missing piece. Some people are sensitized only to Blomia, and a panel focused on European mites will miss them entirely.

Asthma Risk

Across tropical populations, Blo t 21 IgE shows up frequently in people with asthma. In a study of asthmatic children and young adults in equatorial Gabon, a substantial share had IgE against Blo t 21. In the Malaysian patient group, sensitization to Blo t 21 was a risk factor for allergic asthma with notably high odds for the diagnosis.

In a Spanish study of patients with moderate-to-severe type 2 (allergic) asthma, Blo t 21 was commonly recognized and titers were significantly higher in this group, suggesting relevance to more inflammatory and harder-to-control asthma phenotypes. If your asthma is poorly controlled despite standard inhalers, identifying a strong Blomia signal can change the conversation toward allergen-specific immunotherapy.

Atopic Dermatitis

Severe or persistent eczema is often more than a skin problem. In a Czech study of atopic dermatitis patients using a multiplex IgE panel, Blo t 21 was described as a relevant allergen, with Blomia sensitization linked to more severe disease and coexisting asthma or rhinitis. If you have stubborn eczema alongside respiratory symptoms, mite component testing including Blo t 21 can help map the full allergic picture rather than treating each organ in isolation.

Cross-Reactivity and Why the Specific Component Matters

Blomia tropicalis is often confused with the Dermatophagoides mites because they cluster on lab panels and share some proteins. A study of mite-allergic patients in Guangzhou, China showed that most were co-sensitized to all three species, but only some of that overlap is true cross-reactivity. Many people are independently sensitized to each.

Blo t 21 shares part of its amino acid sequence with another Blomia protein, Blo t 5, but IgE inhibition tests show only low-to-moderate cross-reactivity between them. In plain terms, an antibody against Blo t 21 is fairly specific to Blo t 21. That makes it a clean marker of genuine Blomia sensitization rather than a general dust-mite alarm.

Sensitization Rates Across Regions

Sources: Gao et al. 2007 (Singapore); Olajide et al. 2025 (Malaysia); Pauli et al. 2023 (Gabon).

What this means for you: if you grew up in or now live in a tropical or subtropical area, the prior probability that Blomia is a real allergen in your environment is high enough that one negative result on a generic mite panel should not close the case.

Where the Evidence Is Still Thin

Blo t 21 IgE is a useful research and clinical sensitization marker, but it does not have universally standardized thresholds that map onto disease severity in the same way blood pressure or cholesterol numbers do. There are no large, long-running cohort studies that follow Blo t 21 levels over years and tie specific cutoffs to incident asthma, hospitalizations, or other hard outcomes. Treat any single number as one input into the broader picture, not as a verdict.

Tracking Your Trend

Specific IgE levels can shift in response to seasonal mite exposure, treatment, and immune changes over time. One reading tells you whether you are sensitized right now. Two or three readings, spaced months apart, tell you whether your sensitization is intensifying, stable, or fading.

If you start allergen-specific immunotherapy, retesting matters. In a randomized trial of adolescents on sublingual immunotherapy for dust mite allergic rhinitis, Blomia-specific IgE first dropped during the initial six months and then rebounded between six and twelve months, a pattern not seen in placebo. This biphasic response is part of how the immune system is being retrained, so a single mid-treatment number can be misleading.

A reasonable approach: get a baseline before starting any treatment, retest at 3 to 6 months if you are making targeted changes (immunotherapy, serious environmental remediation), and then at least annually to track the long-term trajectory.

When Results Can Be Misleading

A few situations can distort what your blood test shows.

• Polysensitization confusion: if you also have IgE to Dermatophagoides mites, the Blomia result alone does not tell you which mite is driving symptoms. Component testing across multiple mites is needed for clarity.
• Cross-reactivity with related proteins: Blo t 21 has limited but real cross-reactivity with Blo t 5. A positive Blo t 21 IgE is mostly specific to Blo t 21, but co-sensitization to other Blomia components is the norm and should be interpreted together.
• Sensitization without symptoms: a positive IgE means your immune system reacts to the protein, not that you must be symptomatic. Some sensitized people have no clinical allergy. Interpretation always needs to match your symptom history.
• Geographic exposure mismatch: if you live in a temperate region with minimal Blomia exposure, a positive result may reflect cross-reactivity from other mites rather than genuine Blomia-driven disease.

What to Do With an Unexpected Result

If your Blo t 21 IgE comes back positive and you have symptoms, the next step is usually a broader component-resolved panel that includes Blo t 2, Blo t 5, Blo t 10, and the Dermatophagoides components (Der p 1, Der p 2, Der f 1, Der f 2). This map of which mite proteins your immune system recognizes guides the choice of immunotherapy extract. A patient sensitized only to Blomia needs a different shot or sublingual product than someone polysensitized across mites.

An allergist or immunologist is the right specialist to interpret a positive panel and decide whether allergen immunotherapy makes sense for you. If the result is positive but you have no symptoms, that does not require treatment, only awareness, since clinical disease can develop later. If the result is negative but you have classic mite allergy symptoms, push for the broader panel rather than walking away thinking mites are off the hook. Other Blomia components, especially Blo t 2 or Blo t 5, may still be driving your disease.